Dimitrios Chondros - Net Worth and Insider Trading
Dimitrios Chondros Net Worth
The estimated net worth of Dimitrios Chondros is at least $2 Million dollars as of 2024-11-13. Dimitrios Chondros is the SVP, Chief Medical Officer of Halozyme Therapeutics Inc and owns about 38,584 shares of Halozyme Therapeutics Inc (HALO) stock worth over $2 Million. Details can be seen in Dimitrios Chondros's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Dimitrios Chondros has not made any transactions after 2019-08-03 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Dimitrios Chondros
Dimitrios Chondros Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Dimitrios Chondros owns 1 companies in total, including Halozyme Therapeutics Inc (HALO) .
Click here to see the complete history of Dimitrios Chondros’s form 4 insider trades.
Insider Ownership Summary of Dimitrios Chondros
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| HALO | Halozyme Therapeutics Inc | 2019-08-03 | SVP & Chief Medical Officer |
Dimitrios Chondros Latest Holdings Summary
Dimitrios Chondros currently owns a total of 1 stock. Dimitrios Chondros owns 38,584 shares of Halozyme Therapeutics Inc (HALO) as of August 3, 2019, with a value of $2 Million.
Latest Holdings of Dimitrios Chondros
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| HALO | Halozyme Therapeutics Inc | 2019-08-03 | 38,584 | 59.64 | 2,301,150 |
Holding Weightings of Dimitrios Chondros
Dimitrios Chondros Form 4 Trading Tracker
According to the SEC Form 4 filings, Dimitrios Chondros has made a total of 0 transactions in Halozyme Therapeutics Inc (HALO) over the past 5 years. The most-recent trade in Halozyme Therapeutics Inc is the sale of 1,328 shares on August 3, 2019, which brought Dimitrios Chondros around $22,178.
Insider Trading History of Dimitrios Chondros
- 1
Dimitrios Chondros Trading Performance
Dimitrios Chondros Ownership Network
Ownership Network List of Dimitrios Chondros
Ownership Network Relation of Dimitrios Chondros
Dimitrios Chondros Owned Company Details
What does Halozyme Therapeutics Inc do?
Who are the key executives at Halozyme Therapeutics Inc?
Dimitrios Chondros is the SVP & Chief Medical Officer of Halozyme Therapeutics Inc. Other key executives at Halozyme Therapeutics Inc include SVP & Chief Technical Officer Michael J. Labarre , director & President and CEO Helen Torley , and SVP & Chief Financial Officer Nicole Labrosse .
Halozyme Therapeutics Inc (HALO) Insider Trades Summary
Over the past 18 months, Dimitrios Chondros made no insider transaction in Halozyme Therapeutics Inc (HALO). Other recent insider transactions involving Halozyme Therapeutics Inc (HALO) include a net sale of 280,000 shares made by Michael J. Labarre , a net sale of 200,000 shares made by Helen Torley , and a net sale of 49,881 shares made by Matthew L. Posard .
In summary, during the past 3 months, insiders sold 199,881 shares of Halozyme Therapeutics Inc (HALO) in total and bought 0 shares, with a net sale of 199,881 shares. During the past 18 months, 584,881 shares of Halozyme Therapeutics Inc (HALO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 584,881 shares.
Halozyme Therapeutics Inc (HALO)'s detailed insider trading history can be found in Insider Trading Tracker table.
Halozyme Therapeutics Inc Insider Transactions
Dimitrios Chondros Mailing Address
Above is the net worth, insider trading, and ownership report for Dimitrios Chondros. You might contact Dimitrios Chondros via mailing address: 11388 Sorrento Valley Road, San Diego Ca 92121.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
